

Table 1: Clinical Quality Measures in the MCMP Demonstration¹

Diabetes	Heart Failure	Coronary Artery Disease	Preventive Care (<i>measured on population with specified chronic diseases</i>)
DM-1 HbA1c Management	HF-1 Left Ventricular Function Assessment	CAD-1 Antiplatelet Therapy	PC-1 Blood Pressure Measurement
DM-2 HbA1c Control	HF-2 Left Ventricular Ejection Fraction Testing	CAD-2 Drug Therapy for Lowering LDL Cholesterol	PC-5 Breast Cancer Screening
DM-3 Blood Pressure Management	HF-3 Weight Measurement	CAD-3 Beta Blocker Therapy – Prior MI	PC-6 Colorectal Cancer Screening
DM-4 Lipid Measurement	HF-5 Patient Education	CAD-5 Lipid Profile	PC-7 Influenza Vaccination
DM-5 LDL Cholesterol Level	HF-6 Beta Blocker Therapy	CAD-6 LDL Cholesterol Level	PC-8 Pneumonia Vaccination
DM-6 Urine Protein Testing	HF-7 ACE Inhibitor/ARB Therapy	CAD-7 ACE Inhibitor/ARB Therapy	
DM-7 Eye Exam	HF-8 Warfarin Therapy for Patients with AF		
DM-8 Foot Exam			

¹ Updated 1/8/2007. Measure specifications are subject to change and may be updated during the course of the demonstration.

Diabetes Mellitus

1. *HbA1c Management: Testing (DM-1): The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had Hemoglobin A1c (HbA1c) testing*
2. *HbA1c Management: Poor Control (DM-2): The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had HbA1c in poor control (>9.0%)*
3. *Blood Pressure Management (DM-3): The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had a BP < 140/80 mmHg*
4. *Lipid Management Testing: (DM-4): The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had LDL-C screening performed*
5. *Lipid Management: Control < 100mg/dl (DM-5): The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had LDL-C testing < 100 mg/dl*
6. *Urine Protein Screening (DM-6): The percentage of patients 18-75 year of age with diabetes (type 1 or type 2) who had medical attention for nephropathy*
7. *Eye Examination (DM-7): The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had an eye exam (retinal) performed*
8. *Foot Examination (DM-8): The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had a foot exam (visual inspection, sensory exam with monofilament, and pulse exam)*

Congestive Heart Failure

1. *LVF Assessment (HF-1): Percentage of patients with quantitative or qualitative results for LVF assessment*
2. *Left Ventricular Function (LVF) Testing (HF-2): Percentage of patients with LVF testing during the current year for patients hospitalized with a principle diagnosis of HF during the current year*
3. *Weight Measurement (HF-3): Percentage of HF patient visits with weight measurement recorded*
5. *Patient Education (HF-5): Percentage of patients who were provided with patient education on disease management and health behavior changes during one or more visit(s)*
6. *Beta-Blocker Therapy (HF-6): Percentage of patients who were prescribed beta-blocker therapy*

7. *ACE Inhibitor/ARB Therapy (HF-7): Percentage of patients who were prescribed ACE inhibitor or ARB therapy*
8. *Warfarin Therapy for Patients with Atrial Fibrillation (HF-8): Percentage of patients with paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy*

Coronary Artery Disease

1. *Antiplatelet Therapy (CAD-1): Percentage of patients who were prescribed antiplatelet therapy*
2. *Drug Therapy for Lowering LDL Cholesterol (CAD-2): Percentage of patients who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines)*
3. *Beta-Blocker Therapy - Prior Myocardial Infarction (MI) (CAD-3): Percentage of patients with prior MI at anytime who were prescribed beta-blocker therap.*
5. *Lipid Profile (CAD-5): Percentage of patients who received at least one lipid profile (or ALL components tests)*
6. *LDL Cholesterol Level (CAD-6): Percentage of patients with most recent LDL cholesterol <100 mg/dl*
7. *ACE Inhibitor or ARB Therapy (CAD-7): Percentage of patients who also have diabetes and/or LVSD who were prescribed ACE inhibitor or ARB therapy*

Preventive Care

1. *Blood Pressure Measurement (PC-1): Percentage of patient visits with blood pressure (BP) measurement recorded*
5. *Breast Cancer Screening (PC-5): The percentage of women 40-69 years of age who had a mammogram to screen for breast cancer*
6. *Colorectal Cancer Screening (PC-6): Percentage of patients screened for colorectal cancer during the one-year measurement period*
7. *Influenza Immunization (PC-7): Percentage of patients who received an influenza immunization during the one-year measurement period*
8. *Pneumonia Vaccination (PC-8): The percentage of patients ≥ 65 years and older who ever received a pneumococcal vaccination*